Publication ethics — MCQs

10 questions

A 43-year-old woman is hospitalized for chemotherapy following a local recurrence of breast cancer. Because the tumor responded well to the previous chemotherapy regimen, the ordering physician copies and pastes previous recommendations from her electronic health record into the patient’s new orders. Subsequently, the patient develops drug-related toxicity that prolongs her hospital stay. An investigation into the cause shows that she has lost 8 kg (17.6 lb) since her last chemotherapy course, while her other information in recent notes is identical to the past. Which of the following is the most appropriate recommendation to reduce the recurrence of similar types of errors in the future?

A longstanding patient of yours has been hospitalized for a week with pneumonia. You have taken care of her while she was in the hospital. At the end of her hospitalization, she tells you how grateful she is for your care and gives you a small gift basket with homemade food, which you accept. However, when you get home, you realize that the basket also contains a $250 gift certificate to an expensive restaurant. Which of the following is an appropriate response to this situation?

A research team develops a new monoclonal antibody checkpoint inhibitor for advanced melanoma that has shown promise in animal studies as well as high efficacy and low toxicity in early phase human clinical trials. The research team would now like to compare this drug to existing standard of care immunotherapy for advanced melanoma. The research team decides to conduct a non-randomized study where the novel drug will be offered to patients who are deemed to be at risk for toxicity with the current standard of care immunotherapy, while patients without such risk factors will receive the standard treatment. Which of the following best describes the level of evidence that this study can offer?

A 68-year-old man comes to the physician for a follow-up examination, accompanied by his daughter. Two years ago, he was diagnosed with localized prostate cancer, for which he underwent radiation therapy. He moved to the area 1 month ago to be closer to his daughter but continues to live independently. He was recently diagnosed with osteoblastic metastases to the spine and is scheduled to initiate therapy next week. In private, the patient’s daughter says that he has been losing weight and wetting the bed, and she tearfully asks the physician if his prostate cancer has returned. She says that her father has not spoken with her about his health recently. The patient has previously expressed to the physician that he does not want his family members to know about his condition because they “would worry too much.” Which of the following initial statements by the physician is most appropriate?

A researcher is trying to determine whether a newly discovered substance X can be useful in promoting wound healing after surgery. She conducts this study by enrolling the next 100 patients that will be undergoing this surgery and separating them into 2 groups. She decides which patient will be in which group by using a random number generator. Subsequently, she prepares 1 set of syringes with the novel substance X and 1 set of syringes with a saline control. Both of these sets of syringes are unlabeled and the substances inside cannot be distinguished. She gives the surgeon performing the surgery 1 of the syringes and does not inform him nor the patient which syringe was used. After the study is complete, she analyzes all the data that was collected and performs statistical analysis. This study most likely provides which level of evidence for use of substance X?

Which of the following study designs would be most appropriate to investigate the association between electronic cigarette use and the subsequent development of lung cancer?

A psychiatrist receives a call from a patient who expresses thoughts of harming his ex-girlfriend. The patient describes a detailed plan to attack her at her workplace. Which of the following represents the psychiatrist's most appropriate legal obligation?

An academic medical center in the United States is approached by a pharmaceutical company to run a small clinical trial to test the effectiveness of its new drug, compound X. The company wants to know if the measured hemoglobin a1c (Hba1c) of patients with type 2 diabetes receiving metformin and compound X would be lower than that of control subjects receiving only metformin. After a year of study and data analysis, researchers conclude that the control and treatment groups did not differ significantly in their Hba1c levels. However, parallel clinical trials in several other countries found that compound X led to a significant decrease in Hba1c. Interested in the discrepancy between these findings, the company funded a larger study in the United States, which confirmed that compound X decreased Hba1c levels. After compound X was approved by the FDA, and after several years of use in the general population, outcomes data confirmed that it effectively lowered Hba1c levels and increased overall survival. What term best describes the discrepant findings in the initial clinical trial run by institution A?

You are currently employed as a clinical researcher working on clinical trials of a new drug to be used for the treatment of Parkinson's disease. Currently, you have already determined the safe clinical dose of the drug in a healthy patient. You are in the phase of drug development where the drug is studied in patients with the target disease to determine its efficacy. Which of the following phases is this new drug currently in?

Q10

An 83-year-old man presents to the gastroenterologist to follow-up on results from a biopsy of a pancreatic head mass, which the clinician was concerned could be pancreatic cancer. After welcoming the patient and his wife to the clinic, the physician begins to discuss the testing and leads into delivering the results, which showed metastatic pancreatic adenocarcinoma. Before she is able to disclose these findings, the patient stops her and exclaims, "Whatever it is, I don't want to know. Please just make me comfortable in my last months alive. I have made up my mind about this." Which of the following is the most appropriate response on the part of the physician?

Publication ethics US Medical PG Practice Questions and MCQs

Question 1: A 43-year-old woman is hospitalized for chemotherapy following a local recurrence of breast cancer. Because the tumor responded well to the previous chemotherapy regimen, the ordering physician copies and pastes previous recommendations from her electronic health record into the patient’s new orders. Subsequently, the patient develops drug-related toxicity that prolongs her hospital stay. An investigation into the cause shows that she has lost 8 kg (17.6 lb) since her last chemotherapy course, while her other information in recent notes is identical to the past. Which of the following is the most appropriate recommendation to reduce the recurrence of similar types of errors in the future?

A. Using copy and paste only for patient demographics
B. Avoiding copy and paste in electronic health records
C. Preventing identification of authors
D. Limiting copy and paste to lengthy progress notes
E. Making copy and paste material readily identifiable (Correct Answer)

Explanation: ***Making copy and paste material readily identifiable*** - This recommendation directly addresses the root cause of the error: **unnoticed discrepancies** in patient information due to the use of copied and pasted content. - By highlighting copied material, clinicians would be prompted to **critically review** and update the copied information to ensure its accuracy and relevance for the current patient encounter, preventing errors like incorrect chemotherapy dosing based on outdated weight. *Using copy and paste only for patient demographics* - While this might reduce the scope of errors, it overly restricts a potentially useful feature and doesn't address the core problem of **verifying copied data**. - Patient demographics can still change (e.g., address, contact information), so merely limiting copy-paste to this area doesn't eliminate the need for **careful review**. *Avoiding copy and paste in electronic health records* - This is an extreme measure that would significantly reduce efficiency and **increase documentation burden** for clinicians. - Copy-paste can be a valuable tool for efficiency when used appropriately, such as for stable patient histories or standard care plans, provided the copied content is **carefully reviewed**. *Preventing identification of authors* - This recommendation is irrelevant to the described error, which stemmed from a lack of **information verification**, not author identification. - Knowing the author of copied content can actually be helpful for clarification or accountability, so preventing identification would be counterproductive to **quality improvement**. *Limiting copy and paste to lengthy progress notes* - This recommendation still leaves room for significant errors, especially if **critical patient data** within those lengthy notes is copied without verification. - The problem isn't the length of the copied material, but rather the failure to **review and update** it for the current context.

Question 2: A longstanding patient of yours has been hospitalized for a week with pneumonia. You have taken care of her while she was in the hospital. At the end of her hospitalization, she tells you how grateful she is for your care and gives you a small gift basket with homemade food, which you accept. However, when you get home, you realize that the basket also contains a $250 gift certificate to an expensive restaurant. Which of the following is an appropriate response to this situation?

A. Return both the food and gift certificate because it is never acceptable to take gifts from patients
B. Return the gift certificate for cash, and donate the cash to the hospital's free clinic
C. Keep the food, but return the gift certificate (Correct Answer)
D. Keep both the food and gift certificate
E. Report the gifts to your hospital ethics committee

Explanation: ***Keep the food, but return the gift certificate*** - It is generally ethically acceptable to accept **small gifts** of minimal value, especially those that are homemade or symbolic, as they can represent a patient's gratitude and help build rapport. The **homemade food** falls into this category. - However, accepting gifts of **significant monetary value** (like a $250 gift certificate) from patients is usually discouraged as it can create a perception of obligation, influence medical decisions, or exploit the power imbalance inherent in the doctor-patient relationship. These gifts should be respectfully declined or returned. *Return both the food and gift certificate because it is never acceptable to take gifts from patients* - This statement is too extreme; while large gifts are problematic, **small tokens of appreciation** like homemade food are generally permissible and can be beneficial for the therapeutic relationship. - Rejecting all gifts can sometimes be perceived as ungracious or insensitive, potentially harming the **patient-doctor relationship**. *Return the gift certificate for cash, and donate the cash to the hospital's free clinic* - While the intent to donate is admirable, **converting the gift certificate to cash** and then donating it still involves accepting the monetary value of the gift. - This approach does not address the core ethical issue of receiving a **significant financial gift** directly from a patient, which could still create a perceived conflict of interest. *Keep both the food and gift certificate* - Keeping the food is acceptable, but accepting a **$250 gift certificate** is problematic due to its substantial monetary value. - Such a gift could raise concerns about undue influence, the **appearance of impropriety**, or blurring professional boundaries. *Report the gifts to your hospital ethics committee* - While reporting to an ethics committee is appropriate for **significant ethical dilemmas** or violations, accepting a patient's food while returning a gift certificate of high value is a more straightforward ethical decision within established guidelines. - This situation can typically be handled by the physician directly, in accordance with common **ethical principles regarding gifts** from patients, without the need for a formal report to a committee unless there are further complicating factors or uncertainties.

Question 3: A research team develops a new monoclonal antibody checkpoint inhibitor for advanced melanoma that has shown promise in animal studies as well as high efficacy and low toxicity in early phase human clinical trials. The research team would now like to compare this drug to existing standard of care immunotherapy for advanced melanoma. The research team decides to conduct a non-randomized study where the novel drug will be offered to patients who are deemed to be at risk for toxicity with the current standard of care immunotherapy, while patients without such risk factors will receive the standard treatment. Which of the following best describes the level of evidence that this study can offer?

A. Level 1
B. Level 3 (Correct Answer)
C. Level 5
D. Level 4
E. Level 2

Explanation: ***Level 3*** - A **non-randomized controlled trial** like the one described, where patient assignment to treatment groups is based on specific characteristics (risk of toxicity), falls into Level 3 evidence. - This level typically includes **non-randomized controlled trials** and **well-designed cohort studies** with comparison groups, which are prone to selection bias and confounding. - The study compares two treatments but lacks randomization, making it Level 3 evidence. *Level 1* - Level 1 evidence is the **highest level of evidence**, derived from **systematic reviews and meta-analyses** of multiple well-designed randomized controlled trials or large, high-quality randomized controlled trials. - The described study is explicitly stated as non-randomized, ruling out Level 1. *Level 2* - Level 2 evidence involves at least one **well-designed randomized controlled trial** (RCT) or **systematic reviews** of randomized trials. - The current study is *non-randomized*, which means it cannot be classified as Level 2 evidence, as randomization is a key criterion for this level. *Level 4* - Level 4 evidence includes **case series**, **case-control studies**, and **poorly designed cohort or case-control studies**. - While the study is non-randomized, it is a controlled comparative trial rather than a case series or retrospective case-control study, placing it at Level 3. *Level 5* - Level 5 evidence is the **lowest level of evidence**, typically consisting of **expert opinion** without explicit critical appraisal, or based on physiology, bench research, or animal studies. - While the drug was initially tested in animal studies, the current human comparative study offers a higher level of evidence than expert opinion or preclinical data.

Question 4: A 68-year-old man comes to the physician for a follow-up examination, accompanied by his daughter. Two years ago, he was diagnosed with localized prostate cancer, for which he underwent radiation therapy. He moved to the area 1 month ago to be closer to his daughter but continues to live independently. He was recently diagnosed with osteoblastic metastases to the spine and is scheduled to initiate therapy next week. In private, the patient’s daughter says that he has been losing weight and wetting the bed, and she tearfully asks the physician if his prostate cancer has returned. She says that her father has not spoken with her about his health recently. The patient has previously expressed to the physician that he does not want his family members to know about his condition because they “would worry too much.” Which of the following initial statements by the physician is most appropriate?

A. “As your father's physician, I think that it's important that you know that his prostate cancer has returned. However, we are confident that he will respond well to treatment.”
B. “I'm sorry, I can't discuss any information with you without his permission. I recommend that you have an open discussion with your father.” (Correct Answer)
C. “It concerns me that he's not speaking openly with you. I recommend that you seek medical power of attorney for your father. Then, we can legally discuss his diagnosis and treatment options together.”
D. “It’s difficult to deal with parents aging, but I have experience helping families cope. We should sit down with your father and discuss this situation together.”
E. “Your father is very ill and may not want you to know the details. I can imagine it's frustrating for you, but you have to respect his discretion.”

Explanation: ***“I'm sorry, I can't discuss any information with you without his permission. I recommend that you have an open discussion with your father.”*** - This statement upholds **patient confidentiality** and **autonomy**, as the patient explicitly stated he did not want his family to know about his condition. - It encourages communication between the patient and his daughter, which is the most appropriate way for her to learn about his health status. *“As your father's physician, I think that it's important that you know that his prostate cancer has returned. However, we are confident that he will respond well to treatment.”* - This violates the patient's **confidentiality** and explicit wish to keep his medical information private from his family. - Sharing medical information without explicit consent, even with family, is a breach of ethical and legal guidelines (e.g., **HIPAA** in the United States). *“It concerns me that he's not speaking openly with you. I recommend that you seek medical power of attorney for your father. Then, we can legally discuss his diagnosis and treatment options together.”* - While seeking medical power of attorney is an option for future decision-making, it is **premature and inappropriate** to suggest it solely to bypass the patient's current desire for confidentiality, especially when he is still competent to make his own decisions. - This suggestion could undermine the patient's autonomy and trust in his physician. *“It’s difficult to deal with parents aging, but I have experience helping families cope. We should sit down with your father and discuss this situation together.”* - This statement, while empathetic, still risks undermining the patient's **autonomy** by pushing for a joint discussion against his explicit wishes to keep his family unaware. - The physician's primary obligation is to the patient's stated preferences regarding his medical information. *“Your father is very ill and may not want you to know the details. I can imagine it's frustrating for you, but you have to respect his discretion.”* - While this statement acknowledges the daughter's feelings and respects the patient's discretion, it uses a somewhat **judgmental tone** ("very ill") and the phrasing "you have to respect his discretion" can come across as abrupt or dismissive rather than purely informative or guiding. - The most appropriate initial response should focus on the **physician's inability to share information** due to confidentiality rather than attributing motives to the patient's decision or explicitly telling the daughter how to feel.

Question 5: A researcher is trying to determine whether a newly discovered substance X can be useful in promoting wound healing after surgery. She conducts this study by enrolling the next 100 patients that will be undergoing this surgery and separating them into 2 groups. She decides which patient will be in which group by using a random number generator. Subsequently, she prepares 1 set of syringes with the novel substance X and 1 set of syringes with a saline control. Both of these sets of syringes are unlabeled and the substances inside cannot be distinguished. She gives the surgeon performing the surgery 1 of the syringes and does not inform him nor the patient which syringe was used. After the study is complete, she analyzes all the data that was collected and performs statistical analysis. This study most likely provides which level of evidence for use of substance X?

A. Level 3
B. Level 1 (Correct Answer)
C. Level 4
D. Level 5
E. Level 2

Explanation: ***Level 1*** - The study design described is a **randomized controlled trial (RCT)**, which is considered the **highest level of evidence (Level 1)** in the hierarchy of medical evidence. - Key features like **randomization**, **control group**, and **blinding (double-blind)** help minimize bias and strengthen the validity of the findings. *Level 2* - Level 2 evidence typically comprises **well-designed controlled trials without randomization** (non-randomized controlled trials) or **high-quality cohort studies**. - While strong, they do not possess the same level of internal validity as randomized controlled trials. *Level 3* - Level 3 evidence typically includes **case-control studies** or **cohort studies**, which are observational designs and carry a higher risk of bias compared to RCTs. - These studies generally do not involve randomization or intervention assignment by the researchers. *Level 4* - Level 4 evidence is usually derived from **case series** or **poor quality cohort and case-control studies**. - These studies provide descriptive information or investigate associations without strong control for confounding factors. *Level 5* - Level 5 evidence is the **lowest level of evidence**, consisting of **expert opinion** or **animal research/bench research**. - This level lacks human clinical data or systematic investigative rigor needed for higher evidence levels.

Question 6: Which of the following study designs would be most appropriate to investigate the association between electronic cigarette use and the subsequent development of lung cancer?

A. Subjects with lung cancer who smoke and subjects with lung cancer who did not smoke
B. Subjects who smoke electronic cigarettes and subjects who smoke normal cigarettes
C. Subjects with lung cancer who smoke and subjects without lung cancer who smoke
D. Subjects with lung cancer and subjects without lung cancer
E. Subjects who smoke electronic cigarettes and subjects who do not smoke (Correct Answer)

Explanation: ***Subjects who smoke electronic cigarettes and subjects who do not smoke*** - This design represents a **cohort study**, which is ideal for investigating the **incidence** of a disease (lung cancer) in groups exposed and unexposed to a risk factor (electronic cigarette use). - By following these two groups over time, researchers can directly compare the **risk of developing lung cancer** in e-cigarette users versus non-smokers. *Subjects with lung cancer who smoke and subjects with lung cancer who did not smoke* - This option incorrectly compares two groups both with lung cancer, where the exposure to smoking can either be **electronic or traditional cigarettes,** but does not provide a control group without lung cancer to assess the association. - This design would not allow for the calculation of an **incidence rate** or a **relative risk** of lung cancer development specific to electronic cigarette use. *Subjects who smoke electronic cigarettes and subjects who smoke normal cigarettes* - This design compares two different types of smoking, which might be useful for comparing their relative risks but doesn't include a **non-smoking control group** to establish the absolute association with electronic cigarettes. - While it could show if e-cigarettes are "safer" than traditional cigarettes, it wouldn't directly answer whether e-cigarettes themselves **cause lung cancer**. *Subjects with lung cancer who smoke and subjects without lung cancer who smoke* - This describes a **case-control study** but focuses on smoking in general rather than specifically electronic cigarettes, which is the independent variable of interest. - While valuable for identifying risk factors, it would need to specifically differentiate between **electronic cigarette smokers** and other smokers to answer the question adequately. *Subjects with lung cancer and subjects without lung cancer* - This general description of a **case-control study** is too broad; it does not specify the exposure of interest, which is electronic cigarette use. - To be relevant, the study would need to gather data on **electronic cigarette use** in both the lung cancer group and the non-lung cancer control group.

Question 7: A psychiatrist receives a call from a patient who expresses thoughts of harming his ex-girlfriend. The patient describes a detailed plan to attack her at her workplace. Which of the following represents the psychiatrist's most appropriate legal obligation?

A. Warn the ex-girlfriend and notify law enforcement (Correct Answer)
B. Only notify the patient's family
C. Warn only law enforcement
D. Maintain patient confidentiality

Explanation: ***Warn the ex-girlfriend and notify law enforcement*** - This scenario directly triggers the **"duty to warn"** and **"duty to protect"** principles, primarily stemming from the **Tarasoff v. Regents of the University of California** case. - The psychiatrist has a legal obligation to take reasonable steps to protect the identifiable victim, which includes directly warning the intended victim and informing law enforcement. *Only notify the patient's family* - Notifying the patient's family alone does not fulfill the **legal obligation to protect** an identifiable third party from a serious threat of harm. - While family involvement might be part of a comprehensive safety plan, it is insufficient as the sole action in this critical situation. *Warn only law enforcement* - While notifying law enforcement is a crucial step, the **Tarasoff duty** specifically mandates warning the **intended victim** directly (or those who can reasonably be expected to notify the victim). - Relying solely on law enforcement might not ensure the immediate safety of the ex-girlfriend, especially if there's a delay in their response or ability to locate her. *Maintain patient confidentiality* - Patient confidentiality is a cornerstone of psychiatric practice, but it is **not absolute** when there is a serious and imminent threat of harm to an identifiable individual. - The **duty to protect** a potential victim *outweighs* the duty to maintain confidentiality in such extreme circumstances.

Question 8: An academic medical center in the United States is approached by a pharmaceutical company to run a small clinical trial to test the effectiveness of its new drug, compound X. The company wants to know if the measured hemoglobin a1c (Hba1c) of patients with type 2 diabetes receiving metformin and compound X would be lower than that of control subjects receiving only metformin. After a year of study and data analysis, researchers conclude that the control and treatment groups did not differ significantly in their Hba1c levels. However, parallel clinical trials in several other countries found that compound X led to a significant decrease in Hba1c. Interested in the discrepancy between these findings, the company funded a larger study in the United States, which confirmed that compound X decreased Hba1c levels. After compound X was approved by the FDA, and after several years of use in the general population, outcomes data confirmed that it effectively lowered Hba1c levels and increased overall survival. What term best describes the discrepant findings in the initial clinical trial run by institution A?

A. Type I error
B. Hawthorne effect
C. Type II error (Correct Answer)
D. Publication bias
E. Confirmation bias

Explanation: ***Type II error*** - A **Type II error** occurs when a study fails to **reject a false null hypothesis**, meaning it concludes there is no significant difference or effect when one actually exists. - In this case, the initial US trial incorrectly concluded that Compound X had no significant effect on HbA1c, while subsequent larger studies and real-world data proved it did. *Type I error* - A **Type I error** (alpha error) occurs when a study incorrectly **rejects a true null hypothesis**, concluding there is a significant difference or effect when there isn't. - This scenario describes the opposite: the initial study failed to find an effect that genuinely existed, indicating a Type II error, not a Type I error. *Hawthorne effect* - The **Hawthorne effect** is a type of reactivity in which individuals modify an aspect of their behavior in response to their awareness of being observed. - This effect does not explain the initial trial's failure to detect a real drug effect; rather, it relates to participants changing behavior due to study participation itself. *Publication bias* - **Publication bias** occurs when studies with positive or statistically significant results are more likely to be published than those with negative or non-significant results. - While relevant to the literature as a whole, it doesn't explain the discrepancy in findings within a single drug's development where a real effect was initially missed. *Confirmation bias* - **Confirmation bias** is the tendency to search for, interpret, favor, and recall information in a way that confirms one's preexisting beliefs or hypotheses. - This bias would likely lead researchers to *find* an effect if they expected one, or to disregard data that contradicts their beliefs, which is not what happened in the initial trial.

Question 9: You are currently employed as a clinical researcher working on clinical trials of a new drug to be used for the treatment of Parkinson's disease. Currently, you have already determined the safe clinical dose of the drug in a healthy patient. You are in the phase of drug development where the drug is studied in patients with the target disease to determine its efficacy. Which of the following phases is this new drug currently in?

A. Phase 4
B. Phase 1
C. Phase 2 (Correct Answer)
D. Phase 0
E. Phase 3

Explanation: ***Phase 2*** - **Phase 2 trials** involve studying the drug in patients with the target disease to assess its **efficacy** and further evaluate safety, typically involving a few hundred patients. - The question describes a stage after safe dosing in healthy patients (Phase 1) and before large-scale efficacy confirmation (Phase 3), focusing on efficacy in the target population. *Phase 4* - **Phase 4 trials** occur **after a drug has been approved** and marketed, monitoring long-term effects, optimal use, and rare side effects in a diverse patient population. - This phase is conducted post-market approval, whereas the question describes a drug still in development prior to approval. *Phase 1* - **Phase 1 trials** primarily focus on determining the **safety and dosage** of a new drug in a **small group of healthy volunteers** (or sometimes patients with advanced disease if the drug is highly toxic). - The question states that the safe clinical dose in a healthy patient has already been determined, indicating that Phase 1 has been completed. *Phase 0* - **Phase 0 trials** are exploratory, very early-stage studies designed to confirm that the drug reaches the target and acts as intended, typically involving a very small number of doses and participants. - These trials are conducted much earlier in the development process, preceding the determination of safe clinical doses and large-scale efficacy studies. *Phase 3* - **Phase 3 trials** are large-scale studies involving hundreds to thousands of patients to confirm **efficacy**, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug to be used safely. - While Phase 3 does assess efficacy, it follows Phase 2 and is typically conducted on a much larger scale before submitting for regulatory approval.

Question 10: An 83-year-old man presents to the gastroenterologist to follow-up on results from a biopsy of a pancreatic head mass, which the clinician was concerned could be pancreatic cancer. After welcoming the patient and his wife to the clinic, the physician begins to discuss the testing and leads into delivering the results, which showed metastatic pancreatic adenocarcinoma. Before she is able to disclose these findings, the patient stops her and exclaims, "Whatever it is, I don't want to know. Please just make me comfortable in my last months alive. I have made up my mind about this." Which of the following is the most appropriate response on the part of the physician?

A. "If that is your definite wish, then I must honor it" (Correct Answer)
B. "The cancer has spread to your liver"
C. "As a physician, I am obligated to disclose these results to you"
D. "If you don't know what condition you have, I will be unable to be your physician going forward"
E. "Please, sir, I strongly urge you to reconsider your decision"

Explanation: ***"If that is your definite wish, then I must honor it"*** - This response respects the patient's **autonomy** and right to refuse information, aligning with ethical principles of patient-centered care. - The patient has clearly and articulately stated his desire not to know and wishes for **palliative care**, which the physician should respect. - The patient appears to have **decision-making capacity** based on his clear communication of wishes. *"The cancer has spread to your liver"* - This statement violates the patient's explicit request not to be informed of his diagnosis, potentially causing distress and undermining trust. - Disclosure of information against a patient's wishes is unethical when the patient has **decision-making capacity** and has clearly refused information. *"As a physician, I am obligated to disclose these results to you"* - While physicians have a general duty to inform, this is superseded by a **competent patient's right to refuse information**. - No absolute obligation exists to force information upon a patient who explicitly states a desire not to know, especially when it concerns their own health information. *"If you don't know what condition you have, I will be unable to be your physician going forward"* - This response is coercive and threatening, attempting to strong-arm the patient into accepting information he has refused. - A physician's role includes managing symptoms and providing comfort, even if the patient chooses not to know the full diagnostic details of their condition, particularly in a **palliative care** context. - This statement could constitute **patient abandonment**, which is unethical. *"Please, sir, I strongly urge you to reconsider your decision"* - While it's acceptable to ensure the patient fully understands the implications of their decision, a forceful "urge to reconsider" after a clear refusal can be seen as undermining their **autonomy**. - The physician should confirm the patient's understanding and offer an opportunity to discuss it later if desired, rather than immediately pressuring them.

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free